BTIG Maintains Buy on AVITA Medical, Raises Price Target to $11

Benzinga Newsdesk www.benzinga.com Positive 80.2%

Neg 0% Neu 0% Pos 80.2%

BTIG analyst Ryan Zimmerman maintains AVITA Medical (NASDAQ:RCEL) with a Buy and raises the price target from $7 to $11.